Active substanceCefoperazone + SulbactamCefoperazone + Sulbactam
Similar drugsTo uncover
  • Bakperazone
    powder w / m in / in 
  • Baktsefort
    powder w / m in / in 
    KRASFARMA, JSC     Russia
  • Sulzencef®
    powdersolution w / m in / in 
    SYNTHESIS, OJSC     Russia
  • Sulmover®
    powdersolution w / m in / in 
  • Sulmover®
    powdersolution w / m in / in 
  • Sulperazone
    powdersolution w / m in / in 
  • SULPERATEF®
    powdersolution w / m in / in 
    ABOLMED, LLC     Russia
  • Sulceph
    powdersolution w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Cebanex
    powdersolution w / m in / in 
  • Cebanex
    powdersolution w / m in / in 
  • Cefbactam®
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Cefoperazone and Sulbactam Jodas
    powdersolution w / m in / in 
    JODAS EKSPOIM, LLC     Russia
  • Cefoperazone and Sulbactam Spencer
    powdersolution w / m in / in 
    Spencer Pharma UK Limited     United Kingdom
  • Cefpar SV
    powdersolution w / m in / in 
  • Dosage form: & nbsppowder for solution for intravenous and intramuscular administration
    Composition:

    Composition per 1 bottle

    Active substances

    Cefoperazone sodium in terms of cefoperazone - 0.5 g; 1.0 g; 1.5 g; 2.0 g.

    Sulbactam sodium in terms of sulbactam - 0.5 g; 1.0 g; 1.5 g; 2.0 g.

    Description:The powder is white or white with a yellowish hue. Hygroscopic.
    Pharmacotherapeutic group:Antibiotic-cephalosporin + beta-lactamase inhibitor
    ATX: & nbsp

    J.01.D.D.62   Cefoperazone in combination with other drugs

    Pharmacodynamics:

    Antibacterial component of the drug cefoperazone! sulbactam is cefoperazone - Third generation cephalosporin, which acts on sensitive microorganisms during their active propagation by inhibiting the biosynthesis of the mucopeptide of the cell wall. Sulbactam does not have clinically significant antibacterial activity (except for Neisseriaceae and Acinetobacter). However, it was noted that it is an irreversible inhibitor of most of the major beta-lactamases that are produced by microorganisms resistant to beta-lactam antibiotics.

    The ability of sulbactam to prevent the destruction of penicillins and cephalosporins by resistant microorganisms was confirmed in studies using resistant strains for which sulbactam possessed a pronounced synergy with penicillins and cephalosporins.In addition, sulbactam interacts with certain penicillin-binding proteins, so cefoperazone + sulbactam often has a more pronounced effect on sensitive strains than one cefoperazone.

    The combination of sulbactam and cefoperazone is active against all microorganisms sensitive to cefoperazone. In addition, it has a synergistic effect on various microorganisms, primarily: Haemophilus influenzae, Bacteroides spp., Staphylococcus spp., Acinetobacter calcoaceticus, Enterobacter aerogenes, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Morganella morganii, Citrobacter freundii, Enterobacter cloacae, Citrobacter diversus.

    Cefoperazone + sulbactam is active in vitro for a wide range of clinically relevant microorganisms.

    Gram-positive: Staphylococcus aureus (producing and not producing penicillinase), Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes (beta-hemolytic group streptococcus A), Streptococcus agalactiae (beta-hemolytic streptococcus group B), most other strains of beta-hemolytic streptococci, many strains Streptococcus faecal is (enterococci).

    Gram-negative: Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Haemophilus influenzae, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Providencia rettgeri, Providencia spp., Serratia spp. (including Serratia marcescens), Salmonella spp. and Shigella spp., Pseudomonas aeruginosa and some others Pseudomonas spp., Acinetobacter calcoaceticus, Neisseria gonorrhoeae, Neisseria meningitidis, Bordetella pertussis, Yersinia enterocolitica.

    Anaerobic microorganisms

    Gram-negative sticks (including Bacteroides fragilis, others Bacteroides spp. and Fusobacterium spp.).

    Gram-positive and gram-negative cocci (including Peptococcus spp., Peptostreptococcus spp. and Veillonella spp.).

    Gram-positive sticks (including Clostridium spp., Eubacterium spp. and Lactobacillus spp.).

    The following sensitivity levels were established for sulbactam / cefoperazone. The minimum inhibitory concentration (MPC) of μg / ml, expressed in the concentration of cefoperazone, for sensitive microorganisms is less than or equal to 16, for organisms with an intermediate sensitivity of 17 to 63, and for resistant ones - more than 64. Sensitivity zones when determined by a disk diffusion method are: for sensitive microorganisms ≥ 21 mm; with an intermediate sensitivity of 16 to 20 mm, and for resistant ≤ 15 mm.

    To determine the MIC, serial dilutions of sulbactam / cefoperazone can be used in a 1: 1 ratio in broth or agar media. For determination of MPC by disk-diffusion method, it is recommended to use a disc containing 30 μg of sulbactam and 75 μg of cefoperazone.

    The following quality control standards are recommended when using discs containing 30 μg of sulbactam and 75 μg of cefoperazone. For the control strain Acinetobacter spp. (ATCC 43498), the diameter of the zone is 26-32 mm; for Pseudomonas aeruginosa (ATCC 27853) - 22-28 mm; for Escherichia coli (ATCC 25922) - 27-33 mm; for Staphylococcus aureus (ATCC 25923) - 23-30 mm.

    Pharmacokinetics:

    The maximum concentrations (Cmah) of sulbactam and cefoperazone after intravenous administration of 2 g of the drug (1 g of sulbactam, 1 g of cefoperazone) for 5 minutes averaged 130.2 μg / ml and 236.8 μg / ml, respectively. This reflects a higher volume of distribution of sulbactam (Vd = 18.0-27.6 L) compared with that of cefoperazone (Vd = 10.2-11.3 L).

    After intramuscular injection, 1.5 g of sulbactam / cefoperazone (500 mg of sulbactam, 1 g of cefoperazone) Cmsulbactam and cefoperazone in the serum were observed in the period from 15 minutes to 2 hours after administration. FROMmin the serum were 19.0 and 64.2 μg / ml of sulbactam and cefoperazone, respectively.

    Both sulbactam and cefoperazone well distributed into various tissues and body fluids, including bile, gall bladder, skin, appendix, fallopian tubes, ovaries, uterus, etc.

    Approximately 84% of the dose of sulbactam and 25% of the dose of cefoperazone upon administration of the combination cefoperazone + sulbactam are excreted by the kidneys. Most of the remaining dose of cefoperazone is excreted with bile. Cefoperazone Do not displace bilirubin from the connection with plasma proteins. The half-life (T1 / 2) of sulbactam averages about 1 hour, and cefoperazone - 1.7 hours. Serum concentration is proportional to the administered dose. Data on the presence of any pharmacokinetic interaction between cefoperazone and sulbactam when a combination is administered cefoperazone + sulbactam no. When re-applying significant changes in the pharmacokinetics of both components cefoperazone + sulbactam not noted. With the introduction of the drug every 8-12 hours cumulation was not observed.

    Application for violations of the liver. Because cefoperazone is actively excreted in bile, then in patients with liver diseases and / or biliary tract obstruction, T1 / 2 of cefoperazone usually lengthens, and the excretion of the drug by the kidneys increases. Even with a serious violation of liver function in bile, the therapeutic concentration of cefoperazone is reached, and T1 / 2 increases only 2-4 times.

    Use in cases of impaired renal function. In patients with impaired renal function who received cefoperazone + sulbactam, a high correlation was found between the total clearance of sulbactam from the body and the estimated clearance of creatinine.In patients with terminal renal failure, a significant increase in T1 / 2 of sulbactam was found (on average, from 6.9 to 9.7 hours in various studies). Hemodialysis caused significant changes in T1 / 2, the overall clearance and the volume of distribution of sulbactam.

    Application in the elderly. The pharmacokinetics of cefoperazone + sulbactam has been studied in elderly people with renal insufficiency and impaired liver function. In comparison with healthy volunteers, an increase in the duration of T1 / 2, a decrease in clearance and an increase in the volume of distribution of both sulbactam and cefoperazone have been revealed. The pharmacokinetics of sulbactam correlated with the degree of impaired renal function, and the pharmacokinetics of cefoperazone - with a degree of impaired hepatic function.

    Use in children. In studies in children, there were no significant changes in the pharmacokinetics of the components of cefoperazone + sulbactam compared with those in adults. T1 / 2 sulbactam in children ranged from 0.9 to 1.42 h, cefoperazone from 1.44 to 1.88 h.

    Indications:

    Infectious-inflammatory diseases caused by microorganisms sensitive to the preparation:

    - infections of the upper and lower respiratory tract;

    - infections of the kidneys and urinary tract;

    - peritonitis, cholecystitis, cholangitis and other abdominal infections;

    - sepsis;

    - meningitis;

    - skin and soft tissue infections; infection of bones and joints; gonorrhea;

    - inflammatory diseases of the pelvic organs, endometritis, pelvioperitonitis and other infections of the genital tract.

    Contraindications:

    Hypersensitivity to penicillins, sulbactam, cefoperazone or other cephalosporins.

    Carefully:

    Severe hepatic-renal insufficiency. Newborns, incl. premature babies.

    Pregnancy and lactation:

    Proper clinical studies of the drug were not conducted. Cefoperazone + sulbactam penetrates the placental barrier and into breast milk. In pregnancy, the drug apply only if the expected benefit to the mother exceeds the potential risk to the fetus and newborn.

    Dosing and Administration:

    Intravenously (intravenously) (struino and drip) and intramuscularly (IM). With a single dose exceeding 2 g of the drug, preferably iv administration.

    Application in adults. In adults, cefoperazone + sulbactam it is recommended to use in the following daily doses:

    Ratio

    Daily dose, grams

    Cefoperazone + sulbactam

    Sulbactam

    Cefoperazone

    1:1

    2,0-4,0

    1.0-2.0

    1,0-2,0

    The daily dose should be divided into equal parts and administered every 12 hours.

    In severe or refractory infections, the daily dose of the drug cefoperazone + sulbactam can be increased to 8 g at a ratio of the main components of 1: 1 (eg 4 g of cefoperazone). Patients receiving cefoperazone + sulbactam in a ratio of 1: 1, additional administration of cefoperazone may be required. The daily dose of the drug should be divided into equal parts and administered every 12 hours. The recommended maximum daily dose of sulbactam is 4 g.

    Application in renal failure. In patients with creatinine clearance less than 30 mL / min, the dose of the drug cefoperazone + sulbactam is calculated by the dose of sulbactam, as shown in the table below:

    Creatinine clearance

    The maximum dose of sulbactam

    15-30 ml / min

    1 g every 12 h

    less than 15 ml / min

    500 mg every 12 hours

    In severe infections, additional administration of cefoperazone may be required. The pharmacokinetics of sulbactam significantly changes during hemodialysis. The half-life of cefoperazone from the blood serum decreases slightly during hemodialysis.Therefore, the administration of the drug should be planned after dialysis.

    When a violation of liver function Dose changes may be required in cases of severe biliary obstruction, severe liver disease, and renal failure, combined with any of these conditions. In patients with hepatic insufficiency and concomitant renal insufficiency, it is necessary to monitor the concentration of cefoperazone in the serum and dose adjustment if necessary. If the daily dose of cefoperazone does not exceed 2 g, there is no need to monitor its serum concentration.

    Use in children. Children cefoperazone + sulbactam it is recommended to use in the following doses:

    Ratio

    Daily dose, mg / kg / day

    Cefoperazone + sulbactam

    Sulbactam

    Cefoperazone

    1:1

    40-80

    20-40

    20-40

    The dose should be divided into equal parts and administered every 6-12 hours.

    In severe or refractory infections, the daily dose of the drug can be increased to 160 mg / kg / day (with the ratio of the main components 1: 1), which is divided into 2-4 equal parts.

    Newborns During the first week of life, the drug should be injected every 12 hours.The maximum daily dose of sulbactam in children should not exceed 80 mg / kg / day.

    Preparation of solutions for the duration of parenteral administration

    Breeding:

    Dose

    preparation, g

    Equivalent doses

    Cefoperazone + sulbactam, g

    Volume of solvent, ml

    Maximum final

    concentration, mg / ml

    1,0

    0,5+0,5

    3,4

    125+125

    2,0

    1,0+1,0

    6.8

    125+125

    3,0

    1,5+1,5

    10,2

    125+125

    4,0

    2,0+2,0

    13,6

    125+125

    Intramuscular injection. To prepare the solution for the / m administration, use water for injection (see table) or 2% lidocaine solution. 2% lidocaine solution can not be used for the initial dilution of cefoperazone + sulbactam. given their pharmaceutical incompatibility. Compatibility can be achieved by 2-step solution preparation. For primary dilution, use water for injection in the volumes indicated below:

    1,0 g (0.5 g + 0.5 g) of cefoperazone + sulbactam - 2.6 ml;

    2,0 g (1.0 g + 1.0 g) of cefoperazone + sulbactam 5.0 ml.

    Then the resulting solution is diluted with a 2% solution of lidocaine, adding 0.8 ml or 1.7 ml of local anesthetic to the dilution obtained at the initial dilution containing 1.0 g or 2.0 g of cefoperazone + sulbactam, respectively, in order to obtain an antibiotic solution in 0.5% solution of lidocaine.

    Enter deeply intramuscularly in areas of the body with a pronounced muscular layer, for example, the upper-outer quadrant of the buttock).

    Intravenous administration.

    For IV injection the contents of the vial are dissolved as indicated in the table with one of the following infusion solutions: 5% dextrose solution, 0.9% sodium chloride solution, 5% dextrose solution in 0.225% sodium chloride solution, 5% dextrose solution in 0.9% sodium solution chloride or water for injections. The resulting solution is administered for a minimum of 3 minutes.

    For IV infusion, the contents of the vial are dissolved as indicated in the table with one of the following infusion solutions: 5% dextrose solution, 0.9% sodium chloride solution, 5% dextrose solution in 0.225% sodium chloride solution, 5% dextrose solution in 0 , 9% solution of sodium chloride or water for injections; the resulting solution is diluted to 20-100 ml with the same solvent used for the initial dissolution. Enter in / in the drip for 15-60 minutes.

    Drug solutions for intravenous and intramuscular administration prepared using these solvents can be stored for 24 hours at room temperature (25 ° C) or for 48 hours in a refrigerator (2 to 8 ° C).

    Preparation of the solution using Ringer's lactate. Since Ringer's lactate solution is not suitable for initial dilution, the solution is prepared in two steps: first, use water for injection (cf.(see table above), and then the resulting solution is diluted with Ringer's lactate solution to a concentration of 5 mg / ml of sulbactam (each 1 ml of the initial solution is diluted with 25 ml Ringer's lactate solution).

    Side effects:

    Generally cefoperazone + sulbactam well tolerated. The severity of most unwanted reactions was mild and moderate, and they persist until the end of treatment. All undesirable reactions listed in the instructions for medical use of the drug are presented in accordance with the classification MedDRA. In each frequency category, adverse reactions are presented according to the degree of clinical importance.

    Table of unwanted reactions

    Class of organ systems

    Very often ≥1 / 10

    Frequently ≥1 / 100 and <1/10

    Infrequently ≥1 / 1000 and <1/100

    Frequency is unknown (can not be estimated based on available data)

    Violations of the blood and lymphatic system

    Leukopenia§, neutropenia§, a positive direct Coombs reaction§, decreased hemoglobin and hematocrit§. thrombocytopenia§

    Coagulopathy *, eosinophilia§


    Hypoprothrombinemia *

    Immune system disorders




    Anaphylactic shock*ţ, anaphylactic reaction *ţ, anaphylactoid reactionţ (including shock) *, hypersensitivity reactions *ţ

    Disturbances from the nervous system



    Headache


    Vascular disorders




    Bleeding*ţ, vasculitis *, arterial hypotension *

    Disorders from the gastrointestinal tract


    Diarrhea, nausea, vomiting


    Pseudomembranous colitis *

    Disturbances from the liver and bile ducts

    Increased activity of alanine aminotransferase§, aspartate aminotransferase§, alkaline phosphatase in the blood§

    Increase in the concentration of bilirubin in the blood§


    Jaundice*

    Disturbances from the skin and subcutaneous tissue



    Itching, urticaria

    Toxic epidermal necrolysis *ţ, Stevens-Johnson syndrome *ţ, exfoliative dermatitis *ţ, maculopapular rash *

    Disorders from the kidneys and urinary tract




    Hematuria *

    General disorders and disorders at the site of administration



    Phlebitis at the site of infusion, pain and burning at the injection site, fever, chills


    Frequency according to categories CIOMS III (Council of International Medical Scientific Organizations): very often: ≥1 / 10 (≥10%); often: ≥1 / 100 and <1/10 (≥1% and <10%); infrequently: ≥1 / 1000 and <1/100 (≥0.1% and <1%); It is not known: the frequency can not be determined from the available data.

    * Adverse events detected during post-marketing use of the drug.

    § When calculating the frequencies of unwanted reactions in the form of deviations from the norm of the results of laboratory tests, all available data from the results of the analyzes are taken into account, including those of patients whose abnormalities were observed at baseline. This conservative approach was applied, since the baseline data did not allow dividing a subset of patients with baseline deviation of the results of the analyzes, in which significant changes in the results of laboratory tests occurred after initiation of treatment, and a subset of patients with baseline abnormalities of the test results, there were no significant changes in the results of laboratory tests.

    As for the number of leukocytes, neutrophils, platelets, hemoglobin and hematocrit. in reports on studies only abnormalities are reported. It is not indicated whether there has been an increase or decrease in indicators.

    ţ There are reports of fatal cases.

    Overdose:

    Information on the acute toxicity of cefoperazone and sulbactam in humans is limited.

    Symptoms: when an overdose can be expected to occur undesirable effects registered with the use of the drug. A high concentration of beta-lactam antibiotics in the cerebrospinal fluid can lead to neurologic disorders, including convulsions.

    Treatment: symptomatic, hemodialysis is effective, especially in patients with impaired renal function.

    Interaction:

    Drug solutions cefoperazone + sulbactam and aminoglycosides should not be mixed, given the pharmaceutical incompatibility between them. In combination therapy with cefoperazone + sulbactam and aminoglycoside, two drugs are administered by successive infusions using separate secondary catheters, and when using one venous access, the primary catheter is sufficiently well washed between doses of the drugs. The intervals between the administration of cefoperazone + sulbactam and aminoglycoside should be as large as possible during the day.

    When you receive ethanol During treatment with cefoperazone and for up to 5 days after its administration, disulfiram-like effects characterized by "hot flashes", sweating, headache and tachycardia were recorded. Therefore, in patients receiving cefoperazone + sulbactam, which need artificial feeding (inside or parenteral), the use of solutions containing ethanol. When using solutions of Benedict or Felling, a false positive reaction to glucose in the urine can be observed.

    Special instructions:

    The development of hypersensitivity reactions has been reported. in t.ch. leading to a lethal outcome, against the background of beta-lactam antibiotic therapy or cephalosporins, incl. cefoperazonom + sulbactam. Risk of hypersensitivity reactions, incl. leading to death, is higher in patients who have a history of hypersensitivity reactions to many allergens. In case of an allergic reaction, it is necessary to cancel the drug and prescribe adequate therapy. In severe anaphylactic reactions, it is necessary to urgently administer epinephrine, glucocorticosteroids and ensure airway patency, including intubation.

    Patients should be warned about the possibility of disulfiramoid-like effects when taking alcohol while the drug is being treated.

    A dose change may be required in cases of severe obstruction of the biliary tract, severe liver disease,and renal failure, combined with any of these conditions.

    In patients with hepatic insufficiency and concomitant renal failure receiving more than 2 g of cefoperazone per day, it is necessary to monitor the concentration of cefoperazone in the blood serum and adjust its dosage if necessary.

    In the treatment of cefoperazonom in rare cases, a vitamin K deficiency developed. Its cause is probably suppression of normal intestinal microflora, which synthesizes this vitamin. The risk group can include patients receiving malnutrition, with malabsorption syndrome (for example, in cystic fibrosis) and for a long time on intravenous artificial feeding. In such cases, as well as in patients receiving anticoagulants, it is necessary to monitor prothrombin time and, in the presence of indications, prescribe vitamin K.

    With prolonged treatment with cefoperazonom + sulbactam, as with other antibiotics, excessive growth of insensitive microorganisms can be observed.

    Patients should be carefully observed during treatment. With prolonged therapy, it is recommended to periodically monitor the performance of internal organs, including the kidneys,liver and hematopoiesis system. This is especially important for newborns, especially premature and small children.

    Treatment with antibacterial drugs disrupts the normal intestinal microflora, which leads to excessive growth Clostridium difficile. When using almost all antibacterial drugs, including cefoperazone + sulbactam, cases of diarrhea associated with Clostridium difficile. The severity of diarrhea can range from mild forms to severe (pseudomembranous colitis). Clostridium difficile produces toxins A and B, which lead to the development of diarrhea. Diarrhea and pseudomembranous colitis caused by Clostridium difficile, may cause an increase in mortality in patients, and in severe cases, colectomy may be required. If there is a suspicion or diagnosis of pseudomembranous colitis cefoperazone + sulbactam should be abolished and appropriate treatment (metronidazole or Vancomycin oral, enterosorbents, infusion therapy). The use of drugs that inhibit intestinal peristalsis is contraindicated.

    The possibility of developing diarrhea associated with Clostridium difficile, should be considered in all patients with diarrhea that followed the use of antibiotics. Patients who have had diarrhea associated with Clostridium difficile after the introduction of antibacterial drugs, careful medical supervision is necessary for 2 months.

    Use in newborns. Cefoperazone + sulbactam effective in young children. The use of this drug has not been studied extensively in newborns, incl. in premature infants. Thus, prior to initiating drug therapy in preterm infants and newborns, the degree of benefit to the patient and the risk of serious adverse reactions should be assessed.

    Cefoperazone does not displace bilirubin from protein compounds in the blood plasma.

    Effect on the ability to drive transp. cf. and fur:On Based on the clinical experience of the use of cefoperazone + sulbactam, its effect on the ability to drive vehicles and control mechanisms is unlikely.
    Form release / dosage:

    Powder for solution for intravenous and intramuscular injection 0.5 g + 0.5 g, 1.0 g + 1.0 g, 1.5 g + 1.5 g, 2.0 g + 2.0 g.

    Packaging:

    0.5 g + 0.5 g, 1.0 g + 1.0 g, 1.5 g + 1.5 g, 2.0 g + 2.0 g of active substances (in terms of cefoperazone and sulbactam, respectively) in bottles with a capacity of 10 ml or 20 ml of colorless transparent glass, hermetically sealed with rubber stoppers, crimped with aluminum or combined caps.

    1 bottle with instructions for use in a pack of cardboard.

    10 bottles with instructions for use in a cardboard box.

    For hospitals:

    - 50 bottles with an equal number of instructions for use in a carton box:

    - 1 to 50 vials with an equal number of instructions for use in a cardboard box.

    Complete with a solvent.

    Water for injection 5 ml or 10 ml in ampoules of glass.

    For a dosage of 0.5 g + 0.5 g:

    - 1 vial and 1 ampoule 5 ml in a contoured cell packaging (NLC) made of a polyvinyl chloride film with instructions for use in a cardboard package;

    - 5 vials and 5 ampoules of 5 ml each in separate NFC with instructions for use in a pack of cardboard.

    For dosages of 1.0 g + 1.0 g, 1.5 g + 1.5 g and 2.0 g + 2.0 g:

    - 1 vial and 1 ampoule 10 ml or 2 ampoules of 5 ml in the NAV with instructions for use in a pack of cardboard;

    - 5 vials and 5 ampoules of 10 ml or 10 ampoules of 5 ml in separate NDU with instructions for use in a pack of cardboard.

    In the pack put a knife to open the ampoules or a scarifier ampoule. When using ampoules with notches, rings or break points, the ampoule opener opener or ampoule scarifier is allowed not to be inserted.

    Storage conditions:In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:

    2 years.Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-004449
    Date of registration:11.09.2017
    Expiration Date:11.09.2022
    The owner of the registration certificate:KRASFARMA, JSC KRASFARMA, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp05.10.2017
    Illustrated instructions
      Instructions
      Up